AstraZeneca: inhaler cuts mild asthma attacks in study
(CercleFinance.com) - New data showed that AstraZeneca's inhaled drug Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever, the Anglo-Swedish drugmaker said on Monday.
New data from a trial designed to reflect real-world practice has demonstrated the effectiveness of Symbicort Turbuhaler as a potential anti-inflammatory reliever in mild asthma, the company said.
The trial, which compared Symbicort Turbuhaler with two commonly used treatments in mild asthma, showed that AstraZeneca's treatment demonstrated a 51% reduction in the rate of annual asthma exacerbations compared to albuterol.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
New data from a trial designed to reflect real-world practice has demonstrated the effectiveness of Symbicort Turbuhaler as a potential anti-inflammatory reliever in mild asthma, the company said.
The trial, which compared Symbicort Turbuhaler with two commonly used treatments in mild asthma, showed that AstraZeneca's treatment demonstrated a 51% reduction in the rate of annual asthma exacerbations compared to albuterol.
Copyright (c) 2019 CercleFinance.com. All rights reserved.